H.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $30.00 price target on Adverum Biotechnologies (NASDAQ: ADVM)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)August 13, 2024 6:54 AM Adverum Biotechnologies (ADVM) Misses Q2 EPS by 89cAugust 12, 2024 5:14 PM Form 10-Q Adverum Biotechnologies, For: Jun 30August 12, 2024 4:11 PM Form 8-K Adverum Biotechnologies, For: Aug 12August 12, 2024 4:09 PM Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate HighlightsAugust 12, 2024 4:05 PM